

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
04 August 2022 (04.08.2022)



(10) International Publication Number
WO 2022/162088 A3

(51) International Patent Classification:

A61K 31/00 (2006.01) *A61P 35/02* (2006.01)
A61K 9/00 (2006.01) *A61P 37/06* (2006.01)
A61K 31/137 (2006.01) *A61K 31/436* (2006.01)
A61K 31/397 (2006.01) *A61K 31/519* (2006.01)
A61K 31/4245 (2006.01) *A61K 31/5377* (2006.01)
A61K 31/426 (2006.01) *A61K 38/13* (2006.01)
A61K 45/06 (2006.01) *A61K 31/13* (2006.01)
A61P 35/00 (2006.01)

EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(21) International Application Number:

PCT/EP2022/051940

(88) Date of publication of the international search report:

15 September 2022 (15.09.2022)

(22) International Filing Date:

27 January 2022 (27.01.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

PCT/IB2021/000033

28 January 2021 (28.01.2021) IB
21199256.5 27 September 2021 (27.09.2021) EP

(71) Applicants: **PRIOTHERA SAS** [FR/FR]; 57 avenue du Général de Gaulle, 68300 SAINT-LOUIS (FR). **PRIOTHERA LIMITED** [IE/IE]; 88 Harcourt Street, DUBLIN 2, D02 DK18 (IE).

(72) Inventors: **BUCHER, Christoph**; Gassacherweg 27, 4402 FRENKENDORF (CH). **DETSCHNIG, Simone**; Eichenstr. 39, 4054 BASEL (CH).

(74) Agent: **PLASSERAUD IP**; 66 rue de la Chaussée d'Antin, 75440 PARIS CEDEX 09 (FR).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,

(54) Title: METHODS OF TREATMENT WITH SIP RECEPTOR MODULATORS

(57) Abstract: The present invention relates to SIP receptor modulators, preferably mocravimod, for use in treating patients suffering from acute myelogenous leukemia (AML) and who have undergone allogeneic hematopoietic stem cell transplantation (HSCT). The invention relates in particular to methods of treating AML in subjects undergoing HSCT, wherein said method comprises daily administering an efficient amount of SIP receptor modulator, preferably mocravimod, to said subject in need thereof, for at least 6 months, preferably at least 12 months.



WO 2022/162088 A3